1. Academic Validation
  2. Intravenous Iron Sucrose for Children With Iron Deficiency Anemia

Intravenous Iron Sucrose for Children With Iron Deficiency Anemia

  • J Pediatr Hematol Oncol. 2017 Jul;39(5):e259-e262. doi: 10.1097/MPH.0000000000000879.
Kristiyana Kaneva 1 Erika Chow Cathy G Rosenfield Michael J Kelly
Affiliations

Affiliation

  • 1 *Division of Pediatric Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, CA †Tufts University School of Medicine ‡Division of Pediatric Hematology/Oncology, The Floating Hospital for Children at Tufts Medical Center, Boston, MA.
Abstract

Iron deficiency anemia (IDA) is the most common nutritional deficiency in children. Most children with IDA are treated with oral iron preparations. However, intravenous (IV) iron is an alternative for children with severe IDA who have difficulty in adhering to or absorbing oral iron. We sought to describe the safety and effectiveness of IV iron sucrose for treatment of IDA in children. Pharmacy records of children who received IV iron sucrose at a children's hospital between 2004 and 2014 were reviewed. Laboratory markers of anemia and iron studies were obtained and preinfusion and postinfusion values were compared. Records were also reviewed for adverse reactions. A total of 142 patients received IV iron sucrose over 10 years. The mean age was 11 years, 9 months. One patient of 142 developed cough and wheezing during the infusion. No other adverse events were found. IV iron sucrose resulted in a statistically significant and clinically meaningful increase in hemoglobin, mean corpuscular volume, serum iron, ferritin, and % iron saturation, with a corresponding decrease in total iron binding capacity. The use of IV iron sucrose in pediatric patients with IDA is safe and leads to a moderate increase in hemoglobin and substantial improvement in iron studies.

Figures
Products